Skip to main content
Free trial

Ask AI to review this stock

Copy the prompt to get recent events, historical reactions, and a short research brief.

Tell your AI:

Help me set up FinLab and analyze APGE Apogee Therapeutics, Inc.. Please read: https://finlab.finance/en/setup?stock=APGE

No install, open FinLab Studio

APGE

Apogee Therapeutics, Inc. Healthcare As of 2026-08-25 Updated daily after market close

discounted valuation.

2 active signals
52-week adjusted-price high Top-quintile 6-month momentum
Valuation 46Quality 42Growth 59Momentum 98Risk / liquidity 52

Is Apogee Therapeutics, Inc. a buy? Fundamentals and valuation first

  • Valuation is cheaper than most peers. TTM P/E is in the 8th percentile, lower than most liquid US common stocks.

  • Recent volatility is elevated. 60-day annualized volatility is in the 87th percentile. Average 20-day dollar volume is about $170.8M.

  • Signals are active now. 52-week adjusted-price high, Top-quintile 6-month momentum currently holds; the tables below show what followed in this stock’s own history.

Watchlist

This page refreshes daily after the close. Add Apogee Therapeutics, Inc. to your watchlist to track signal changes on your next visit.

Historical evidence

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

52-week adjusted-price high

Active

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

4 historical occurrences (since 2025-11-11)

Top-quintile 6-month momentum

Active · now 94.99575911789653%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

4 historical occurrences (since 2024-01-12)

Market-wide momentum baseline

Across 97,637 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.19%, a 58.1% positive-return rate, and +2.83 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

Filed revenue acceleration

Pending

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.